BTAI BioXcel Therapeutics Earnings per share increase in current year

BioXcel Therapeutics (BTAI) is implementing AI to develop neurological drugs, offering the innovative IGALMI for injection-free bipolar disorder therapy. Development optimization is accelerating entry into niche markets, which confirms the annual EPS trend. Meanwhile, 52.60 represents the latest value for this metric. Business stability is ensured by the Western localization of patents, creating a safe haven for the company's operational activities.

Earnings per share growth in current year: BioXcel Therapeutics Inc (BTAI) for 07/04/2022 - 09/19/2026

Financial and market metric breakdowns for BioXcel Therapeutics (BTAI)

- market value and analyst target forecast:

Stock Price BioXcel Therapeutics Inc|BTAI - Price Target Chart

- market capitalization data:

Market Value BioXcel Therapeutics Corp|BTAI - Total Company Value

- business book valuation details:

Net Asset Value per Share BioXcel Therapeutics|BTAI - Company Book Value|Market Value to Book Value Ratio bioxceltherapeutics.com|BTAI - Aggregate Company Assets

- debt and liquidity details:

- company profitability and valuation multiples indicators:

BTAI - Company Net Income|Expected Net Profit BioXcel Therapeutics|BTAI - Price to Earnings Ratio|Price to Future Earnings Ratio BioXcel Therapeutics Corp|BTAI - PEG Multiple|Enterprise Value to EBITDA Ratio BioXcel Therapeutics Corp|BTAI - Operating profit EBITDA|Net earnings per one share for the last twelve months BioXcel Therapeutics|BTAI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months bioxceltherapeutics.com|BTAI - Net earnings per share growth this year|Expected earnings per share trend next year BioXcel Therapeutics

- revenue and sales proceeds data:

BTAI - Company Sales|Company Projected Revenue Volume BioXcel Therapeutics Inc|BTAI - P/S Multiple|Forward Price to Sales BioXcel Therapeutics Corp

Summary company analysis:BTAI BioXcel Therapeutics Inc

Signature product of BioXcel Therapeutics

This metric measures the annual dynamics of earnings per share, reflecting the efficiency of value generation for shareholders. For BioXcel Therapeutics (BTAI), this metric is critical as it demonstrates the pace of loss reduction against R&D expenditures. Analyzing YoY EPS changes allows for tracking the impact of the cash burn rate on the final financial result. An increase in this indicator signals an approach toward the break-even point. This is a key marker of business model sustainability during the period preceding the commercial success of its drugs.

Direct competitors